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Abstract 
Background: Chemotherapy-induced nausea and vomiting (CINV) is a major adverse toxicity of cancer chemother-
apy. Recommended treatments for prevention of CINV vary among published guidelines, and optimal care for CINV 
caused by moderately emetogenic chemotherapy has not been established. This study assessed the efficacy and 
safety of triple antiemetic therapy comprising palonosetron, dexamethasone and aprepitant for carboplatin-based 
chemotherapy. Chemotherapy-naïve patients with lung cancer scheduled for a first course of a carboplatin-contain-
ing regimen formed the study cohort. Patients were pretreated with antiemetic therapy comprising palonosetron 
(0.75 mg, i.v.) and dexamethasone (9.9 mg, i.v.) on day 1, and aprepitant (125 mg, p.o.) on day 1 followed by 80 mg on 
days 2 and 3. Primary endpoint was the proportion of patients who did not experience vomiting and did not require 
rescue medication [complete response (CR)] in the acute phase (0–24 h), late phase (24–168 h) and overall. Second-
ary endpoint was the proportion of patients who experienced no vomiting episodes and no more than mild nausea 
without the need for rescue medication [complete control (CC)].
Results: Prevalence of a CR during the acute phase, delayed phase, and overall was 100, 91.9 and 91.9%, whereas 
that of CC was 100, 84.4 and 84.4%, respectively. The most common adverse event was mild constipation; severe 
adverse events related to antiemetic treatment were not observed.
Conclusion: Triple antiemetic therapy comprising palonosetron, dexamethasone and aprepitant shows excellent 
effects in the prevention of CINV in patients receiving a carboplatin-containing regimen.
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Background
Despite the introduction of antiemetic treatments such 
as corticosteroids, 5-hydroxytryptamine-3 (5-HT3) 
receptor antagonists, and neurokinin-1 (NK-1) receptor 
inhibitors, chemotherapy-induced nausea and vomiting 
(CINV) remains a major toxicity of cancer chemotherapy 
that reduces the quality of life (QOL) of cancer patients.
In guidelines relating to clinical practice, chemother-
apy drugs are classified according to their “emetogenic-
ity”. Guidelines state that antiemetic treatments should 
be adopted according to the category of emetic risks, 
but there are some differences in the recommendations 
for moderately emetogenic chemotherapy (MEC) among 
such guidelines. Guidelines set by the American Soci-
ety of Clinical Oncology recommend a two-drug com-
bination comprising palonosetron and dexamethasone 
as antiemetic treatment for MEC (Basch et al. 2011). In 
contrast, guidelines set by the National Comprehensive 
Cancer Network recommend a double combination of 
a 5-HT3 receptor antagonist and dexamethasone, and 
an additional NK-1 inhibitor (e.g., aprepitant) is rec-
ommended for patients treated with a carboplatin- or 
irinotecan-containing regimen (Ettinger et  al. 2012). 
The standard of care indicated by these guidelines 
has improved the prevalence of emetic events mark-
edly, but almost half of patients continue to suffer acute 
and delayed CINV after MEC (Di Maio et  al. 2015). 
Antiemetic therapy should aim to minimize or eliminate 
CINV in an optimal manner in all cancer patients, so the 
methods of CINV control can be improved further.
Recently, the Multinational Association of Support-
ive Care in Cancer (MASCC) and the European Society 
of Medical Oncology (ESMO) updated the guidelines 
for prevention of chemotherapy- and radiotherapy-
induced nausea and vomiting (Roila et  al. 2016). Previ-
ous MASCC/ESMO guidelines recommended the 5-HT3 
receptor antagonist palonosetron plus dexamethasone 
for prophylaxis of acute nausea and vomiting; also, dexa-
methasone (p.o.) taken for several days has been recom-
mended as preferred treatment for delayed emesis in 
MEC-treated patients (Roila et  al. 2010). According to 
the MASCC/ESMO guidelines updated in 2016, a 5-HT3 
receptor antagonist and dexamethasone is recommended 
for the prevention of acute emesis. Whether palonose-
tron in combination with dexamethasone is superior to 
other 5-HT3 receptor antagonists in MEC regimens is 
not clear, owing to a lack of comparative studies.
The effect of an NK-1 inhibitor arises from allevia-
tion of the emetic effects of substance P on the central 
chemotrigger zone (Saito et al. 2009; Schmitt et al. 2014). 
Several large studies have shown that addition of aprepi-
tant to a regimen containing granisetron or ondansetron 
and dexamethasone can significantly improve prevention 
of acute and delayed emesis for patients receiving highly 
emetogenic chemotherapy (HEC) (Stoltz et al. 2004; Cur-
ran and Robinson 2009).
According to the MASCC/ESMO guidelines, routine 
prophylaxis with an NK-1 receptor antagonist is not 
included for patients administered MEC. Conversely, the 
benefit of an aprepitant-containing triple antiemetic regi-
men for a broad range of MEC regimens has also been 
reported (Rapoport et al. 2010). The role of a NK-1 inhib-
itor with a second-generation 5-HT3 receptor antagonist 
as a prophylactic agent is also not clear.
Carboplatin in combination with third-generation 
antitumor agents is used widely as first-line chemother-
apy for advanced non-small-cell lung cancer (NSCLC). 
Carboplatin is classified as a MEC agent, but carbopl-
atin-containing combination chemotherapy, such as car-
boplatin plus pemetrexed, has high emetogenic potential 
(Ito et al. 2014). Antiemetic efficacy may not be satisfac-
tory if only a 5-HT3 receptor antagonist and dexametha-
sone are administered for prevention of CINV in patients 
receiving carboplatin-based combination chemotherapy.
Considering the various mechanisms of actions of 
antiemetic drugs, appropriate combinations must be 
investigated. Chemotherapy agents categorized as MEC 
contain a wide spectrum of emetic potential, and there 
are few data on the emetic potential of combination 
chemotherapy. For prophylaxis of CINV, the effective-
ness of combination treatment with an NK-1 inhibitor 
and first-generation 5-HT3 antagonist has been reported. 
However, the efficacy of a regimen comprising palonose-
tron, an NK-1 inhibitor, and dexamethasone for MEC has 
not been investigated thoroughly. We wished to assess 
the efficacy and feasibility of the strongest regimen (palo-
nosetron, dexamethasone, aprepitant) as prophylactic 
treatment for patients receiving carboplatin-containing 
MEC.
Patients and methods
This clinical trial was conducted as a phase-II, prospec-
tive, multicenter study of the East Japan Chesters Group. 
The study protocol was in accordance with the Declara-
tion of Helsinki and registered at the University Hospital 
Medical Information Network Clinical Trials Registry as 
UMIN000017877. After approval from the Institutional 
Review Board of each participating institute, patients 
who had provided written informed consent were 
enrolled in seven hospitals between September 2011 and 
September 2014.
Patient population
Chemotherapy-naïve patients, except those with lung 
cancer, receiving epidermal growth factor receptor tyros-
ine kinase inhibitors formed the study cohort. Eligible 
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patients were adults (age  >  20  years) with lung cancer 
confirmed by histology or cytology scheduled for a first 
course of a carboplatin-containing regimen (area under 
the curve for carboplatin  =  5 or 6). Patients were also 
required to have adequate hematologic, hepatic and renal 
functions in laboratory tests, adequate oral intake and an 
Eastern Cooperative Oncology Group performance sta-
tus (PS) of 0, 1, or 2.
Patients were excluded if they had any of the follow-
ing: (i) malignancy of the central nervous system or other 
causes of nausea or vomiting unrelated to chemotherapy 
(e.g., gastrointestinal obstruction, massive ascites); (ii) 
active infection; (iii) uncontrolled pleural effusions; (iv) 
concomitant radiation therapy; (v) an emetic episode 
24  h before initiation of chemotherapy; (vi) complica-
tions that prohibited dexamethasone use. Patients could 
not receive radiotherapy within 30  days before chemo-
therapy initiation.
Before the study commenced, an informed-consent 
form detailing the study procedure and its associated 
risks was explained to each patient. Any drugs with 
antiemetic efficacy other than the study drugs were not 
allowed before the study started, and were recorded on 
a medical chart if administered during the study period.
Study design
Efficacy and safety of antiemetic therapy were assessed 
during an observation period from the administration 
of chemotherapy to day 7 (168  h). Patients were pro-
vided with a daily questionnaire to record any vomiting 
episode, rate their nausea, and to state dietary intake. 
Patients assessed their nausea and QOL using a 100-mm 
horizontal visual analog scale and with the Functional 
Living Index-Emesis (Martin et al. 2003). Tests of blood 
chemistry were undertaken before chemotherapy and 
days 6 or 7 to evaluate adverse effects. Adverse events, 
use of rescue therapy, and laboratory data were recorded 
on the medical chart. Patients were treated with triple 
antiemetic therapy comprising intravenous administra-
tion of 0.75 mg palonosetron and 9.9 mg dexamethasone 
on day 1, and oral administration of 125  mg aprepitant 
on day 1 followed by 80  mg on days 2 and 3. A dexa-
methasone dose ≤24 mg was allowed for patients being 
pre-medicated with paclitaxel according to the package 
insert.
Objectives
Primary endpoint of the present study was the pro-
portion of patients who did not experience vomiting 
and who did not require rescue medication [complete 
response (CR)] in the acute phase (0–24 h) and late phase 
(24–168  h). Secondary endpoint was the proportion of 
patients who experienced no vomiting episodes and no 
more than mild nausea without rescue medication [com-
plete control (CC)]. Other endpoints were grade of nau-
sea in acute and delayed phases, daily dietary intake, and 
QOL.
Statistical analyses
The sample size was calculated to be ≥90 patients based 
on the assumption that the prevalence of a CR would 
be ≤70% (null hypothesis). The alternative hypothesis 
was that the prevalence of a CR would be >75% with an 
alpha value of 5% and power of 80%. Taking into account 
that some patients would be lost to follow-up, the total 
sample size required was determined to be ≥90 patients. 
Statistical analyses were done using SPSS (IBM, Armonk, 
NY, USA).
Results
Ninety-two patients were enrolled between November 
2010 and September 2014. As two patients were excluded 
from analyses because of a lack of efficacy data, 90 
patients were included for analyses.
Patient characteristics are summarized in Table 1. Sev-
enty-two patients were male and 18 patients were female 
(median age, 69 years). Eighty patients had NSCLC and 
10 had small-cell lung cancer. Most of the patients had 
good PS (0 to 1), except for five patients with a PS of 2. 
Of the chemotherapeutic treatments that contained car-
boplatin, paclitaxel was the most common (given to 35 
patients, 38.8%), whereas pemetrexed, TS-1, etoposide, 
and docetaxel were given to 24 (26.6%), 13 (15.5%), 12 
(14.4%) and six (6.6%) patients, respectively.
Efficacy
As no patients had a vomiting episode within 24 h from 
the start of chemotherapy, the prevalence of a CR in the 
acute phase was 100% (Fig.  1). Prevalence of a CR in 
Table 1 Patient characteristics
Sex Male/female 72/18
Type of malignancy Small-cell lung cancer 10
Non-small-cell lung cancer 80
Performance status 0 35
1 50
2 5
Median age (range), years 69 (38–82)
Chemotherapy regimen
Carboplatin + paclitaxel 35
Carboplatin + pemetrexed 24
Carboplatin + TS-1 13
Carboplatin + etoposide 12
Carboplatin + docetaxel 6
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the delayed phase (24–168 h) and overall (0–168 h) was 
91.9%. Prevalence of a CR on individual days was 98.8% 
on day 2, 97.7% on day 3, 92.3% on day 4, 96.4% on day 5, 
94.0% on day 6, and 97.0% on day 7 (Fig. 2).
As no patients experienced vomiting or more than mild 
nausea, the prevalence of a CC in the acute phase was 
100% (Fig.  3). Prevalence of a CC in the delayed phase 
and overall was 84.9%. Prevalence of CC on individual 
days was 97.8% on day 2, 92.2% on day 3, 88.9% on day 
4, 91.1% on day 5, 91.1% on day 6, and 96.7% on day 7 
(Fig. 2).
Male patients tended to have a higher prevalence of a 
CR and CC in the delayed phase compared with female 
patients. Prevalence of a CR in the delayed phase was 
94.2% in male patients and 82.4% in female patients 
(Fig.  1). Prevalence of a CC in the delayed phase was 
87.0% in male patients and 76.5% in female patients 
(Fig. 3).
Meal intake on individual days is shown in Fig.  4. 
Before the start of chemotherapy, 86.6% of patients ate 
























Fig. 1 Complete response (CR) according to phase. This bar graph 
shows the percentage of patients achieving a CR 168 h after initiation 
of chemotherapy. A CR was defined as no vomiting and no require-
ment of rescue medication. Blue bar denotes all patients; red bar 



























Fig. 2 Time-course of a complete response (CR) over a 24-h period. 
This bar graph shows the percentage of patients achieving a CR and 
complete control (CC) on individual days after initiation of chemo-
therapy. Blue and red bars show the percentage achieving a CR and 
CC, respectively. A CR was defined as no vomiting and no use of 
rescue mediation. A CC was defied as no vomiting, no significant 





























Fig. 3 Complete control (CC) according to phase. This bar graph 
shows the percentage of patients achieving CC 168 h after initiation 
of chemotherapy. Blue bar denotes all patients; red bar denotes male 





























Fig. 4 Meal intake over a 24-h period. This bar graph shows the 
percentage of patients according to food intake before and after ini-
tiation of chemotherapy. Blue bar denotes the percentage of patients 
who ate >71% of a meal served in hospital; red bar, 70–51%; green bar, 
50–31%; purple bar, <30%
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decreases in dietary intake in the delayed phase. The pro-
portions of patients who ate >71% of a meal served on 
days 4, 5 and 6 were 50, 44 and 55%, respectively.
Safety
The most common adverse events exceeding grade 3 of 
the Common Terminology Criteria for Adverse Events 
(CTCAE) were neutropenia (5 cases), hypertension (5), 
diarrhea (1), and proteinuria (1), caused presumably by 
chemotherapy drugs (Table 2). No severe adverse events 
related to antiemetic treatment exceeding grade 3 of the 
CTCAE were observed, except for hypertension. The 
most common adverse event associated with antiemetic 
treatment was constipation (grade 1, 39 cases; grade 2, 
4 cases). All patients were treated successfully by anti-
constipation drugs and no specialized treatment (e.g., 
enema) was required to control constipation symptoms.
Discussion
In Japan, some patients are hesitant to receive cancer 
chemotherapy because they are afraid of adverse effects 
such as CINV. Much progress has been made in support-
ive care, but clinical experts frequently underestimate 
the severity of nausea and vomiting, and many patients 
suffer from CINV without optimal management of symp-
toms (Di Maio et al. 2015). The aim of antiemetic therapy 
should be to minimize or eliminate CINV in all cancer 
patients. However, recommended treatments for CINV 
vary among guidelines, and half of patients receiving 
MEC are afflicted by CINV (Ihbe-Heffinger et al. 2004). 
An investigational study to establish optimal antiemetic 
treatment for MEC is thus warranted.
Several studies have reported that combination treat-
ment using a 5-HT3 receptor antagonist, an NK-1 
receptor inhibitor, and dexamethasone are useful for 
prevention of the CINV caused by HEC (Miura et  al. 
2013; Longo et al. 2011). Triple therapy comprising palo-
nosetron, aprepitant and dexamethasone seems to be 
the strongest antiemetic treatment. Miura et  al. (2013) 
reported on the efficacy of triple treatment for CINV 
in lung-cancer patients receiving HEC. Prevalence of 
a CR and CC overall was 81.1 and 66.7%, respectively, 
and treatment carried a good safety profile. None of the 
severe adverse events exceeded grade 3 of the CTCAE. 
Mild constipation that was readily manageable was 
reported to be the most common adverse effect. Con-
sidering the excellent profile of that treatment, triple 
therapy should be investigated as prophylaxis against the 
CINV observed with MEC.
Warr et al. (2005) demonstrated that addition of aprep-
itant to ondansetron and dexamethasone enhances the 
antiemetic effect of MEC using cyclophosphamide plus 
doxorubicin or epirubicin (AC). However, the prevalence 
of a CR was only 51% in the aprepitant group and only 
42% in the control group over 5  days. Grunberg et  al. 
(2009) reported on the efficacy of a triple regimen com-
prising palonosetron, dexamethasone and aprepitant for 
prevention of acute and delayed CINV caused by MEC. 
Prevalence of a CR was relatively good in the acute phase 
(76%), but was not satisfactory overall (51%). Those 
results are confusing because most patients were treated 
with an AC regimen, which is now classified as HEC in 
the MASCC/ESMO guidelines. The value of antiemetic 
treatment should be evaluated more strictly according to 
the respective characteristics of each chemotherapy drug.
The MASCC/ESMO guidelines updated in 2016 state 
that addition of an NK-1 inhibitor to a 5-HT3 receptor 
antagonist and dexamethasone is recommended to pre-
vent carboplatin-induced acute nausea and vomiting 
(Roila et al. 2016). Ito et al. (2014) reported a randomized 
phase-2 trial that compared standard antiemetic ther-
apy with a 5-HT3 receptor antagonist and dexametha-
sone with aprepitant add-on triple antiemetic therapy in 
patients with NSCLC who received carboplatin-based 
first-line chemotherapy. The aprepitant group showed a 
better overall CR of 80.3% compared with that of 67.2% 
for the control group. Tanioka et al. (2013) reported on a 
randomized study of aprepitant in women receiving MEC 
comprising mainly a carboplatin- or irinotecan-contain-
ing regimen. Prevalence of a CR overall was superior, but 
not significantly higher, in the aprepitant, granisetron 
and dexamethasone group than in the placebo, granise-
tron and dexamethasone group (aprepitant group, 62.2%; 
placebo group, 52.1%). The authors concluded that the 
addition of aprepitant seemed to be effective and that 
Table 2 Treatment-related adverse events
Grade-4 treatment-related adverse events were not reported
ALT alanine aminotransferase, AST aspartate aminotransferase, LDH lactate 
dehydrogenase, BUN blood urea nitrogen
Grade 1 Grade 2 Grade 3
Constipation 39 4 0
Hiccups 13 6 0
Hypertension 20 11 5
Cough 9 1 0
Insomnia 8 1 0
Fatigue 14 3 0
Increased LDH 20 1 0
Increased ALT 10 1 0
Increased AST 8 0 0
Increased BUN 19 0 0
Hypocalcemia 14 2 0
Hyperkalemia 6 1 0
Hyponatremia 17 0 0
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an antiemetic regimen equivalent to that used for HEC 
was well tolerated and seemed to be more effective for 
CINV prevention in women receiving MEC. Use of palo-
nosetron instead of granisetron might improve delayed 
CINV because American Society of Clinical Oncology 
guidelines recommend palonosetron as the preferred 
5-HT3 receptor antagonist for a non-AC MEC regimen 
(Basch et  al. 2011). However, no clinically relevant dif-
ferences between palonosetron and other 5-HT3 recep-
tor antagonists have been demonstrated by randomized 
trials for a non-AC MEC regimen. There is a lack of 
evidence of comparative studies in MEC agents dem-
onstrating an advantage of the use of palonosetron with 
respect to other 5-HT3 receptor antagonists. According 
to the general rule of MASCC/ESMO guidelines, a ben-
efit of ≥10% is sufficiently clinically meaningful to war-
rant a change in guidelines. In our study, triple antiemetic 
therapy comprising palonosetron, dexamethasone, and 
aprepitant achieved a CR of 100 and 91.9% in acute and 
delayed phases, respectively. These data suggest that tri-
ple antiemetic therapy could increase the prevalence of a 
CR by ≥10%. Hence, the efficacy of triple therapy should 
be investigated.
Results of antiemetic studies in patients treated with 
MEC are summarized in Table  3. Celio et  al. (2011) 
reported that the prevalence of a CR in the acute phase 
and delayed phase was 88.6 and 68.7%, respectively, in 
patients treated with palonosetron and dexamethasone 
as antiemetic treatment. Prevalence of a CR in other 
reports treated MEC not specified regimen tended to 
be equal or less than in that report. In the present study, 
the chemotherapy regimens administered to enrolled 
patients were based on carboplatin. Prevalence of a CR 
in the acute phase and delayed phase was excellent (100 
and 91.9%, respectively). Prevalence of a CR was remark-
ably better than that in other studies stating that palo-
nosetron, dexamethasone and aprepitant is the strongest 
antiemetic treatment that produces excellent antiemetic 
effects against MEC using a carboplatin-based regimen.
Hesketh et  al. (2016) reported that addition of rolapi-
tant to a 5-HT3 receptor antagonist and dexametha-
sone provided patients who received carboplatin-based 
chemotherapy with superior protection against CINV. 
Prevalence of a CR was significantly higher with rolapi-
tant treatment than that achieved with the control overall 
and in the delayed phase. Prevalence of a CR in the acute 
phase was 91.7%, which is close to that obtained in the 
present study.
The mechanism of action of delayed CINV is not 
entirely understood, but it is considered to be differ-
ent to that of acute CINV. Delayed CINV is thought to 
arise through the effects of substance P in the central 
chemotrigger zone (Curran and Robinson 2009). Even 
though the introduction of a first-generation 5-HT3 
receptor antagonist has elicited significant improve-
ments in prophylactic care against CINV, control of 
delayed emesis remains an unaddressed need. Schmoll 
et  al. (2006) reported that a 5-HT3 receptor antago-
nist administered on multiple occasions may be more 
effective than a 5-HT3 receptor antagonist adminis-
tered once for control of delayed CINV. Palonosetron 
is a second-generation selective antagonist against the 
5-HT3 receptor that has an ≈100-fold stronger bind-
ing affinity for the 5-HT3 receptor compared with first-
generation agents, and an extended plasma elimination 
half-life of ≈40 h (Aporo et al. 2006). If the long half-life 
Table 3 Summary of studies focusing on the efficacy of antiemetic therapy in patients receiving MEC
Doses of Ap were the standard doses recommended by various guidelines such as 125 mg on day 1 and 80 mg on days 2 and 3. “MEC” in the chemotherapy column 
indicates that the MEC was not specified
CR complete response, Palo palonosetron, Gra granisetron, Dex dexamethasone, Ap aprepitant, Rol rolapitant, MEC moderately emetogenic chemotherapy, CBDCA 
carboplatin, PAC paclitaxel
Author Regimen (mg) Acute CR (%) Delayed CR (%) Overall CR (%) Chemotherapy
Eisenberg et al. (2003) Palo (0.25) 63 54 46 MEC
Palo (0.75) 57.1 56.6 47.1
Celio et al. (2011) Palo (0.25) + Dex (8) day 1 88.6 68.7 67.5 MEC
Palo (0.25) + Dex (8) days 1-3 84.3 77.7 71.1
Tanioka et al. (2013) Gra (1) + Dex (12) + Ap 97.8 62.2 62.2 CBDCA-based
Gra (1) + Dex(12) 95.7 52.2 52.2
Hesketh et al. (2016) Gra (2) day1-3 + Dex (20) + Rol (180) 91.7 82.3 80.2 CBDCA-based
Gra (2 mg) days1-3 + Dex (20 mg) 88.0 65.6 64.6
Yahata et al. (2016) Gra (1/4) + Dex (20) + Ap 94.0 63.6 61.6 CBDCA + PAC
Gra (1/4) + Dex (20) 90.4 49.3 47.3
Present study Palo (0.75) + Dex (9.9) + Ap 100 91.9 91.9 CBDCA-based
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of palonosetron compensates for the effect of the delayed 
phase, a single dose of palonosetron could be more con-
venient than multiple doses of a first-generation 5-HT3 
receptor antagonist. Roscoe et  al. (2012) presented data 
from a double-blind randomized clinical trial for control 
of delayed nausea. They reported that addition of dexa-
methasone on days 2 and 3 reduced CINV in the delayed 
phase. Conversely, Celio et al. (2013) demonstrated that a 
dexamethasone-sparing regimen is not associated with a 
significant loss in overall antiemetic protection in women 
undergoing AC if palonosetron is used as an antiemetic.
The beneficial effect of an NK-1 inhibitor for control 
of delayed CINV is also controversial. Efficacy of addi-
tion of aprepitant for control of delayed CINV has been 
reported to be identical to that elicited by addition of 
prochlorperazine (an antipsychotic drug that acts on 
dopaminergic receptors at the chemoreceptor trigger 
zone) (Roscoe et al. 2012). Olanzapine is another antip-
sychotic drug whose effect is manifested through block-
ade of multiple neurotransmitter receptors. Navari et al. 
(2016) reported on a randomized, double-blind, phase-3 
trial comparing olanzapine with placebo, in combination 
with dexamethasone, aprepitant or fosaprepitant, and 
5-HT3 receptor antagonist in patients receiving cisplatin 
or AC. Olanzapine significantly improved nausea preven-
tion, as well as the prevalence of a CR, among patients 
receiving HEC. They concluded that olanzapine was a 
very promising candidate for control of acute and delayed 
CINV in patients receiving HEC.
In the present study, the prevalence of a CR and CC in 
the delayed phase was excellent (91.9 and 84.9%, respec-
tively), but dietary intake decreased significantly on days 
3 to 6. Admittedly, there is room for improvement in 
treatment of delayed nausea, but the triple regimen has 
a tremendous effect on patients receiving MEC based on 
carboplatin.
This clinical trial assessed the efficacy of triple treat-
ment only in the first cycle of chemotherapy. However, 
sustained efficacy of the same antiemetic regimen has 
been reported throughout repeat chemotherapy cycles in 
a population receiving HEC (Sakai et al. 2008). Control of 
CINV in the first cycle is important because the CINV of 
subsequent cycles and anticipatory emesis are related to 
the degree of CINV of the first cycle (Chan et al. 2015). 
Maximally effective antiemetics as first-line therapy 
should be used rather than withholding more effective 
drugs for subsequent use at the time of antiemetic failure.
Being female and young is considered to contribute 
to the variance in acute nausea and severity of delayed 
nausea when chemotherapy is administered (Molassiotis 
et al. 2014). In our study, the prevalence of a CR and CC 
was consistently better for male patients, but the number 
of patients was not sufficient to power statistical analyses. 
Future clinical trials should consider differences in CINV 
prevalence according to sex. The cost of medication is 
another important issue: the antiemetic drugs evaluated 
in our study are indicated and covered by insurance from 
the Japanese government.
Conclusions
We demonstrated the excellent effect of a triple regimen 
comprising palonosetron, dexamethasone and aprepi-
tant as prophylactic care for patients treated with a car-
boplatin-containing regimen. This triple regimen did not 
enhance adverse effects. If the “ultimate” goal in CINV 
research is absence of CINV in patients undergoing 
chemotherapy, use of the triple regimen described here 
could be a candidate.
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